hVIVO plc (LON:HVO – Get Free Report)’s stock price shot up 10% on Monday . The company traded as high as GBX 22 ($0.27) and last traded at GBX 21.25 ($0.26). 7,804,669 shares were traded during mid-day trading, an increase of 164% from the average session volume of 2,961,263 shares. The stock had previously closed at GBX 19.33 ($0.24).
hVIVO Stock Performance
The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The company has a 50 day simple moving average of GBX 20.25 and a 200-day simple moving average of GBX 25.68. The firm has a market cap of £144.58 million, a PE ratio of 708.33 and a beta of 0.97.
hVIVO Company Profile
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Read More
- Five stocks we like better than hVIVO
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Sizing Up a New Opportunity for NVIDIA Investors
- Using the MarketBeat Dividend Tax Calculator
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- What Are Dividend Challengers?
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
